Trupanion, Inc. $TRUP Shares Bought by Tudor Investment Corp ET AL
Tudor Investment Corp significantly increased its stake in Trupanion (NASDAQ:TRUP) by 183.7% in Q3, now owning 237,125 shares worth $10.26 million. Despite insider selling, other institutional investors have also adjusted their positions. Analysts maintain a consensus "Hold" rating with a target price of $44.50, following recent earnings that slightly missed EPS expectations but beat revenue.
John Gallagher Sells 430 Shares of Trupanion (NASDAQ:TRUP) Stock
Trupanion COO John Gallagher sold 430 shares of the company's stock on March 30th for $10,952.10, reducing his ownership by 1.33%. This comes as Trupanion recently missed quarterly EPS estimates and has received numerous downgrades from analysts, leading to a consensus "Hold" rating and a price target of $44.50. Despite institutional investors increasing their stakes, the company's stock has seen a decline from its 12-month high.
Insider Sell: John Gallagher Sells Shares of Trupanion Inc (TRUP)
John Gallagher, Chief Operating Officer of Trupanion Managers USA Inc., sold 430 shares of Trupanion Inc (TRUP) on March 30, 2026, reducing his total holdings to 31,957 shares. Trupanion Inc, a pet insurance provider, has seen 26 insider sells and no insider buys in the past year. The stock is currently trading at $25.47, with a market cap of $1.104 billion, and is considered significantly undervalued based on its GF Value of $40.61.
TRUPANION (TRUP) COO sells 430 shares under Rule 10b5-1 plan
TRUPANION (TRUP) Chief Operating Officer John R. Gallagher sold 430 shares of common stock at $25.47 per share on March 30, 2026. This transaction was conducted under a pre-established Rule 10b5-1 trading plan, with Gallagher retaining 31,957 shares directly after the sale. The sale, valued at approximately $10,952, was for financial diversification, and the timing was not at the discretion of the reporting person.
Trupanion (TRUP) COO Gallagher sells $10952 in stock
Trupanion Inc. (TRUP) Chief Operating Officer John R. Gallagher sold 430 shares of company stock for $10,952 on March 30, 2026, under a pre-arranged trading plan. This sale occurred while the stock is near its 52-week low, although InvestingPro analysis suggests it may be undervalued. The company recently reported mixed Q4 2025 results with revenue exceeding expectations but EPS falling short, and has strategic partnerships and analyst rating adjustments.
Trupanion (TRUP) COO Gallagher sells $10952 in stock
Trupanion Inc. COO John R. Gallagher sold 430 shares of company stock worth $10,952 on March 30, 2026, under a pre-arranged trading plan. This sale occurred while TRUP shares were near their 52-week low. The company recently reported mixed Q4 2025 earnings, with EPS missing forecasts but revenue exceeding expectations, and Stifel lowered its price target due to competitive concerns.
How Trupanion Inc. (TRUP) Affects Rotational Strategy Timing
This article analyzes Trupanion Inc. (TRUP) using AI models, identifying a stable neutral reading in shorter horizons that could alleviate a long-term weak bias. It details three trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis. The report highlights an exceptional 98.3:1 risk-reward setup, targeting a 29.3% gain against a 0.3% risk.
Stifel Lowers Price Target for Trupanion (TRUP) to $31, Maintains Hold Rating | TRUP Stock News
Stifel analyst Jonathan Block has lowered the price target for Trupanion (TRUP) to $31.00 from $35.00, representing an 11.43% decrease, while maintaining a "Hold" rating. This adjustment reflects ongoing market evaluations, with other analysts also revising their targets for TRUP in recent months. Trupanion, a specialty pet insurance provider, faces continued scrutiny from investors and stakeholders.
Stifel Nicolaus Has Lowered Expectations for Trupanion (NASDAQ:TRUP) Stock Price
Stifel Nicolaus has lowered its price target for Trupanion (NASDAQ:TRUP) from $35 to $31, maintaining a "hold" rating, while the analyst consensus remains a "Hold" with an average target of $44.50. The stock is currently trading near its 1-year low with a P/E of 56.65, indicating a rich valuation. Recent financial reports show the company missed EPS expectations slightly at $0.13 but had an 11.7% revenue growth, and insiders have been selling shares.
Trupanion, Inc. (TRUP) PT Lowered to $31 at Stifel: 'Scale Remains Elusive'
Stifel analyst Jonathan Block lowered the price target for Trupanion, Inc. (TRUP) to $31, citing that "scale remains elusive" for the company. This article, published on StreetInsider.com, is a premium-only piece, requiring a subscription to read in full.
TRUP (NASDAQ: TRUP) Rule 144: insider sales of 5,713 shares reported
Trupanion (NASDAQ: TRUP) filed a Rule 144 notice detailing planned sales of restricted common stock and disclosing past sales by John Gallagher. The filing indicates 430 shares of restricted stock from May 25, 2023, and 180 shares from February 25, 2023, are slated for sale. It also reports two prior sales by John Gallagher totaling 5,713 shares, executed on February 27, 2026, and January 28, 2026, for a combined value of $153,698.43.
Vanguard Realignment Reports 0 Shares for Trupanion (NASDAQ: TRUP)
Vanguard has filed an amended Schedule 13G/A for Trupanion (NASDAQ: TRUP), reporting zero beneficial ownership of common stock due to an internal realignment effective January 12, 2026. This realignment, made under SEC Release No. 34-39538, means certain Vanguard subsidiaries will now report their ownership separately. Investors are advised to look for subsequent filings from Vanguard affiliates to understand consolidated holdings.
Small-Cap Stock Analysis 2026: Thermon, Novanta, Trupanion Review - News and Statistics
StockStory's analysis of small-cap stocks highlights Thermon as a strong performer due to its market share gains, significant revenue growth, expanding operating margin, and outpaced EPS growth. Conversely, Novanta faces challenges with below-expectation revenue expansion, slower EPS growth than revenue, and decreasing free cash flow margin. Trupanion also shows concerning financial metrics, including no book value per share growth over five years, projected slowdown in growth, and a negative return on equity.
Does Trupanion’s (TRUP) HABRI Partnership Deepen Its Health-Centric Brand or Dilute Its Core Focus?
Trupanion (TRUP) has partnered with the Human Animal Bond Research Institute (HABRI) to link pet insurance with scientific research on the human-animal bond, including support for veterans and service dogs. This collaboration aims to strengthen Trupanion's brand and align with its data and health insights initiatives. While seen as positive for brand alignment, investors are advised to monitor customer acquisition costs and competitive pressures, which remain key factors in Trupanion's investment narrative.
Does Trupanion’s (TRUP) HABRI Partnership Deepen Its Health-Centric Brand or Dilute Its Core Focus?
Trupanion (TRUP) has partnered with the Human Animal Bond Research Institute (HABRI) to link pet insurance with scientific research on the human–animal bond, including supporting veterans and service dogs. This collaboration aims to strengthen Trupanion's brand through mission alignment and may support efficiency improvements and margin sustenance in the long run. However, investors are still urged to consider factors like rising customer acquisition costs and competitive pressures, despite growth forecasts and a projected 76% upside to its current price according to Simply Wall St's analysis.
Trupanion Inc stock turns profitability corner after strong Q2 2025 earnings beat on NASDAQ
Trupanion Inc (NASDAQ: TRUP) reported a significant Q2 2025 earnings beat, with EPS of $0.22 against expected -$0.03 and a revenue increase of 12.3% to $353.56 million. This performance signals a crucial shift towards profitability for the pet insurance provider, driven by improved operational efficiency, membership growth, and strategic investments in technology. The company's positive outlook, coupled with analyst upgrades and an expanding pet care market, positions it as a compelling investment despite potential risks like rising veterinary inflation and competition.
Tudor Investment Corp ET AL Has $10.26 Million Holdings in Trupanion, Inc. $TRUP
Tudor Investment Corp ET AL significantly increased its stake in Trupanion, Inc. (NASDAQ:TRUP) by 183.7% in Q3, now holding 237,125 shares valued at $10.26 million. Despite this, Trupanion has seen recent insider selling, with CFO Fawwad Qureshi and COO John R. Gallagher selling shares totaling over $215,000. Analysts currently rate TRUP as a "Hold" with a consensus target price of $45.50, following a Q4 earnings report that missed EPS estimates.
Trupanion Inc stock faces earnings scrutiny after Q4 miss as pet insurance demand grows
Trupanion Inc reported Q4 2025 EPS of $0.13, slightly missing estimates, despite continued revenue growth in the expanding pet insurance market. The company faces scrutiny regarding its profitability and upcoming Q1 2026 results. The article highlights market dynamics, risks, and investor relevance for DACH markets, emphasizing the balance between growth potential and profitability challenges.
Trupanion Inc stock faces earnings scrutiny after Q4 miss as pet insurance demand grows
Trupanion Inc. reported its Q4 2025 earnings, missing EPS estimates by $0.01 with $0.13, despite continued revenue growth. Profitability remains a concern for investors, prompting close scrutiny of upcoming Q1 2026 results. The company operates in a growing pet insurance market driven by rising pet ownership and veterinary costs, leveraging its direct-to-consumer model and comprehensive coverage, while facing challenges like high acquisition costs and competition.
TRUP PE Ratio & Valuation, Is TRUP Overvalued
This article assesses the valuation of Trupanion Inc (TRUP), concluding that it is currently in the "Fair zone" with a fair price range of $17.32 to $80.19 based on relative valuation. While TRUP's P/S ratio of 1.05 is 48.45% above the industry average, the article suggests this premium might be unsustainable given its 11.72% revenue growth. Key metrics like P/B ratio, FCF yield, and Forward P/E are also provided, showing its P/B ratio is lower than its 3-year and 5-year averages, but its FCF yield is significantly lower than past averages.
Trupanion, Inc. Stock Hits New 52-Week Low at $24.34
Trupanion, Inc. (TRUP) stock plummeted to a new 52-week low of $24.34 on March 19, 2026, marking an 8.96% decline over the past year. Despite this recent downturn, the company demonstrates strong long-term fundamentals with significant growth in operating profits (85.81% CAGR), net sales (23.45% annually), and a robust net profit surge of 239.98% over the last five quarters. Trupanion maintains a market capitalization of USD 1,125 million, with a P/E ratio of 55.00 and an ROE of 5.32%, suggesting operational strength despite current stock price challenges.
Trupanion stock hits 52-week low at $24.49 as challenges persist
Trupanion Inc. (TRUP) stock recently hit a new 52-week low of $24.49, reflecting a 33.06% decline over the past year and substantial drops more recently, driven by market challenges and competitive pressures. Despite these struggles, the company is expanding its customer base and product offerings, and InvestingPro data suggests the stock might be undervalued given its 0.19 PEG ratio. Trupanion also reported mixed Q4 2025 earnings, missing EPS estimates but exceeding revenue forecasts, and announced a new partnership with the Human Animal Bond Research Institute for research initiatives.
Trupanion stock hits 52-week low at $24.49 as challenges persist
Trupanion Inc. (TRUP) stock recently hit a 52-week low of $24.49, reflecting a significant decline over the past year and year-to-date due to market challenges and competitive pressures in the pet insurance industry. Despite investor concerns, InvestingPro data suggests the stock may be undervalued with an attractive PEG ratio, and the company continues to focus on customer base expansion and product enhancements. Trupanion also reported a mixed Q4 2025 earnings with an EPS miss but a revenue beat, and announced a new partnership for human-animal bond research.
Trupanion (TRUP) surpasses $1B in subscription revenue and returns to profitability in 2025
This article from MSN discusses Trupanion's financial performance, highlighting its achievement of over $1 billion in subscription revenue. The pet insurance company is also projected to return to profitability in 2025, indicating a significant financial turnaround and growth trajectory.
Assessing Trupanion (TRUP) Valuation After New HABRI Partnership On Service Dog Research
Trupanion (TRUP) shares are in focus after a new partnership with the Human Animal Bond Research Institute (HABRI) for service dog research. Despite the mission-driven story, the stock has experienced recent selling pressure with declines over the past 90 days and one year. Analysts view Trupanion as undervalued, with a fair value of $46.25 against a current trading price of $24.74, although its high P/E ratio of 55.3x raises questions about embedded growth expectations.
Assessing Trupanion (TRUP) Valuation After New HABRI Partnership On Service Dog Research
Trupanion (TRUP) recently partnered with the Human Animal Bond Research Institute (HABRI) for service dog research, but the stock has seen significant declines. Despite analysts' consensus price target of $56.5 and a fair value estimate of $46.25 suggesting undervaluation, the company's high P/E ratio of 55.3x compared to the industry average raises concerns about its growth expectations. Investors are advised to consider the full risk and reward picture, including potential risks to subscriber growth and competitive pressures.
Trupanion, Inc. Hits New 52-Week Low at $24.50 Amid Market Challenges
Trupanion, Inc. has reached a new 52-week low of $24.50, marking an 11.71% stock performance drop over the past year. Despite this short-term decline, the company exhibits strong long-term fundamentals with an 85.81% CAGR in operating profits and consistent net sales growth. Trupanion's market capitalization stands at USD 1,289 million with a P/E ratio of 119.00, indicating robust growth potential despite current market challenges.
Is Trupanion’s (TRUP) HABRI Partnership Quietly Redefining Its Evidence-Based Pet Care Strategy?
Trupanion (TRUP) recently announced a partnership with the Human Animal Bond Research Institute (HABRI) focusing on veterans and service dogs, which aligns with its mission but is not expected to be a direct financial driver in the short term. The company's main catalyst remains sustaining profitable growth after achieving its first full year of GAAP profitability in 2025 with $19.43 million in net income. While the HABRI partnership is good for brand reputation, investors should also consider the challenges of rising pet acquisition costs and modest new pet additions for Trupanion's future performance.
Trupanion Inc expected to post a loss of 3 cents a share - Earnings Preview
Trupanion Inc (TRUP) is projected to report a loss of 3 cents per share and a 10.1% increase in quarterly revenue to $346.673 million when it releases its results for the period ending June 30, 2025. Analysts currently rate the shares as a "buy" with a median 12-month price target of $56.00, suggesting a 15.5% upside from its last closing price. The company's guidance for the quarter included revenue between $344.00 million and $350.00 million and EBIT between USD27 million and USD30 million.
Trupanion HABRI Alliance Adds New Dimension To Pet Insurance Story
Trupanion (TRUP) announced a partnership with the Human Animal Bond Research Institute (HABRI) to focus on research and advocacy supporting the human-animal connection. This collaboration aims to use data-driven insights to inform programs benefiting pet and human welfare, potentially deepening Trupanion's ties with various groups and influencing brand perception. For investors, this alliance offers a new dimension to watch beyond traditional metrics, linking Trupanion's brand to research on how pets support human health.
Trupanion HABRI Alliance Adds New Dimension To Pet Insurance Story
Trupanion has partnered with the Human Animal Bond Research Institute (HABRI) to focus on research and advocacy supporting the human-animal connection. This collaboration aims to use data-driven insights to inform programs and policies, potentially strengthening Trupanion's brand perception and enhancing its appeal to various groups, including veterans and organizations focused on health. While unlikely to immediately boost revenue, the alliance could foster deeper relationships and differentiate Trupanion in the pet insurance market.
Trupanion stock hits 52-week low at $25.23
Trupanion Inc. (TRUP) stock has fallen to a new 52-week low of $25.23, marking a significant 45% decline from its 52-week high and a 22.65% decrease over the past year. Despite this downturn, InvestingPro analysis suggests the stock may be undervalued, with an attractive PEG ratio pointing to potential future upside. The company recently reported mixed Q4 2025 earnings, falling short on EPS but exceeding revenue expectations, and announced a new partnership with the Human Animal Bond Research Institute.
Trupanion, Inc. Stock Hits New 52-Week Low at $25.11
Trupanion, Inc. (TRUP) stock has fallen to a new 52-week low of $25.11, marking a 10.17% decrease over the past year, contrasting with broader market gains. Despite this decline, the company exhibits strong long-term fundamentals, including an 85.81% CAGR in operating profits and consistent quarterly growth in net sales. High institutional holdings suggest continued investor interest despite recent stock performance challenges.
3 Risky Russell 2000 Stocks: Mission Produce, Insteel, Trupanion Analysis 2026 - News and Statistics
An analysis of the Russell 2000 index identifies three small-cap stocks—Mission Produce, Insteel Industries, and Trupanion—that present significant investor concerns in 2026. Mission Produce faces declining revenue and lower gross margins, while Insteel Industries struggles with modest sales growth and reduced free cash flow due to high capital expenditures. Trupanion has not increased its book value per share and reports negative return on equity, suggesting investors should look for alternative opportunities within the small-cap market.
Trupanion (TRUP) Valuation Check After Insider Selling And Mixed Quarterly Earnings Results
Trupanion (TRUP) is being reviewed after insider selling and mixed quarterly results showing revenue growth but lower earnings per share. Despite a current trading price of US$27.44 which is significantly below the analyst target of US$46.25, the company faces high P/E ratios and valuation risk. Investors are advised to conduct their own analysis, considering the potential growth and margin improvements needed to justify the target valuation, and to be aware of risks like over-reliance on price increases or increased competition.
Trupanion outlines 14% subscription revenue growth target for 2026 while highlighting record retention and margin gains
Trupanion aims for a 14% subscription revenue growth target by 2026, driven by record high member retention and improvements in its gross margin. The company plans to achieve this through an underwriting profit at historical run rate, supported by recent price adjustments. These strategic moves are expected to enhance financial performance and sustained growth.
Insider Sell: Emily Dreyer Sells 7,792 Shares of Trupanion Inc (TRUP)
Emily Dreyer, Chief Revenue Officer of a Trupanion Inc subsidiary, sold 7,792 shares of TRUP on March 4, 2026. This transaction follows a pattern of insider selling, with Dreyer having sold 21,817 shares over the past year and no insider buys reported for the company. Despite the insider selling, Trupanion Inc's stock is considered significantly undervalued based on its GuruFocus Value.
Insider Selling: Trupanion (NASDAQ:TRUP) CRO Sells 7,792 Shares of Stock
Trupanion's Chief Revenue Officer, Emily Dreyer, recently sold 7,792 shares of the company's stock for approximately $219,345, reducing her stake by nearly 18%. This transaction comes as Trupanion is trading near its 52-week low and slightly missed its latest EPS estimates despite year-over-year revenue growth. Analysts generally rate TRUP as a "Hold" with an average price target of $45.50.
Trupanion (TRUP): Buy, Sell, or Hold Post Q4 Earnings?
Trupanion (TRUP) stock has dropped 33.7% in the past six months, trading at $28.77, prompting investors to question its future. The article advises against buying Trupanion due to substandard BVPS growth of 10.4% annually over the last two years and a negative average return on equity of -7.5% over five years, indicating limited asset expansion and poor performance compared to peers. While not a terrible business, its high risk and 2.8x forward P/B valuation suggest better investment opportunities exist elsewhere.
TRUPANION (TRUP) Chief Revenue Officer sells 7,792 shares at $28.15
TRUPANION Chief Revenue Officer Emily Dreyer sold 7,792 shares of company common stock on March 4, 2026, at an average price of $28.1468 per share. Following this transaction, Dreyer directly holds 35,627 shares. The sale was reported in a Form 4 SEC filing, indicating an open-market transaction.
[144] TRUPANION, INC. SEC Filing
This article reports on a Form 144 SEC filing by Trupanion, Inc. (TRUP), which is a notice of proposed sale of securities under Rule 144. The filing details the sale of 7792 shares of common stock, acquired as restricted stock on May 25, 2022, with an aggregate market value of $219,319.87, to be sold on NASDAQ via Morgan Stanley Smith Barney LLC on March 4, 2026. The document includes filer and issuer information, securities to be sold, and a declaration by the seller regarding material adverse information.
Vanguard Group Inc. Has $153.80 Million Stake in Trupanion, Inc. $TRUP
Vanguard Group Inc. reduced its stake in Trupanion, Inc. by 1.8% in the third quarter, holding 3,553,613 shares valued at $153.8 million. Despite Vanguard's reduction, other institutional investors like Millennium Management LLC, JPMorgan Chase & Co., Geode Capital Management LLC, and Invesco Ltd. increased their holdings. Trupanion, a pet medical insurance company, has a market capitalization of $1.19 billion and recently reported EPS of $0.13, missing estimates, while revenue increased by 11.7% year-over-year.
Insider Selling: Trupanion (NASDAQ:TRUP) COO Sells $140,105.16 in Stock
Trupanion's COO, John Gallagher, sold 5,283 shares of the company's stock for over $140,000, reducing his position by 14.02%. This transaction occurred as the stock trades below its 50-day and 200-day moving averages, and the company recently missed Q4 EPS estimates. Analysts currently have a "Hold" rating on TRUP with an average target price of $45.50.
Trupanion (NASDAQ:TRUP) CFO Sells $75,067.02 in Stock
Trupanion's CFO, Fawwad Qureshi, sold a total of 7,482 shares worth approximately $194,000 in late February. This comes as the company reported Q4 EPS of $0.13, missing consensus by $0.01, and revenue of $376.85 million, an 11.7% year-over-year increase. Several analysts have downgraded Trupanion's stock and cut price targets, resulting in a consensus "Hold" rating with an average target price of $45.50.
Trupanion (TRUP) CFO logs 2,837-share 10b5-1 stock sale at $26.46
Trupanion's Chief Financial Officer, Fawwad Qureshi, reported the sale of 2,837 shares of common stock at a weighted average price of $26.4629 per share on February 27, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan established on May 19, 2025, and resulted in Qureshi holding no directly owned shares of the company following the sale. The filing indicates that the sale was for financial diversification, and the CFO had no discretion over the timing of the transaction.
Trupanion (TRUP) COO sells 5,283 shares in Rule 10b5-1 trade
Trupanion's Chief Operating Officer, John R. Gallagher, sold 5,283 shares of common stock on February 27, 2026, at a weighted average price of $26.5153 per share. This sale was conducted under a pre-established Rule 10b5-1 trading plan for financial diversification, meaning Gallagher had no control over the timing. Following this transaction, he directly owns 32,387 shares of the company.
Trupanion’s Return To Profitability And Pricing Shift Might Change The Case For Investing In TRUP
Trupanion (TRUP) reported a strong return to profitability in 2025, with net income of US$19.4 million and revenues exceeding US$1.00 billion, largely due to price adjustments. The company projects continued revenue growth for 2026 and is exploring lower-priced offerings. While analysts have varying expectations, the core investment narrative hinges on disciplined pricing, customer retention, and efficient pet acquisition, with a key risk being that growth is still driven more by price increases than new pet additions.
Citigroup Inc. Decreases Stock Position in Trupanion, Inc. $TRUP
Citigroup Inc. significantly reduced its stake in Trupanion, Inc. (NASDAQ:TRUP) by 22.7% in the third quarter of 2025, selling over 40,000 shares. This move comes as Trupanion's insiders also sold shares, and several analysts downgraded the stock or cut price targets following Q3 earnings that missed consensus estimates. Despite this, other institutional investors increased their holdings in the pet insurance provider.
Assessing Trupanion (TRUP) Valuation After Profitability Return And US$1b Subscription Revenue Milestone
Trupanion (TRUP) has returned to profitability in 2025 with US$1B in subscription revenue, yet its share price has declined recently. A "Most Popular Narrative" suggests the stock is 42.6% undervalued with a fair value of $46.25, driven by improved underwriting and growth. However, concerns remain regarding its high P/E ratio of 59.3x compared to the industry average of 12x, which could indicate a "priced for perfection" valuation.
[Form 4] TRUPANION, INC. Insider Trading Activity
Simon Wheeler, EVP of Trupanion International, engaged in a routine stock compensation activity. On February 25, 2026, he exercised 322 restricted stock units (RSUs) which converted into 322 common shares. Subsequently, 151 common shares were sold at $26.70 per share to cover tax withholding obligations related to the RSU vesting, resulting in Wheeler directly owning 23,087 common shares.
